Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Advertisement
Set Alert for Articles By Neena Brizmohun

Latest From Neena Brizmohun

Some Drug Prices Could Drop 40% Under Canada’s Cost Lowering Proposals

The prices of patented medicines overall are expected to go down in Canada under new proposed regulatory amendments.

Pricing Debate Canada

EMA Points Out Shortfalls To Avoid When Seeking Novel Methodology Qualification

A new EMA checklist of “essential considerations” for the successful qualification of novel methodologies covers common issues that have compromised applications for qualification in the past.

Research & Development Research and Development Strategies

Australia, Canada, Switzerland, Singapore Test Simultaneous Authorizations For Generics

Generic drug makers are being invited to take part in a trial that could help them get their products approved simultaneously in Australia, Canada, Switzerland and Singapore.

Drug Review Australia

Australian Online Tool To Take Tedium Out Of Identifying New PI

The TGA says that its new search function to help generic drug sponsors identify new and updated product information will become more valuable over time.

Post Market Regulation & Studies Drug Safety

EMA Stands By Recommendation To Suspend Modified-Release Paracetamol From Market

The EMA’s drug safety committee has re-examined its recommendation in September to suspend modified-release paracetamol at the request of two companies that sell such products.

Drug Safety Post Market Regulation & Studies

Australia Cancels More Urogynecological Mesh Licenses

Registrations for certain transvaginal mesh products are being cancelled by the Australian Therapeutic Goods Administration, and conditions on other mesh and sling products are being imposed.

Safety Gynecology & Urology
See All
Advertisement
UsernamePublicRestriction

Register